Shares of TherapeuticsMD Inc (NASDAQ:TXMD) shot up 6.9% during mid-day trading on Tuesday . The company traded as high as $6.48 and last traded at $6.36. 3,189,117 shares changed hands during trading, an increase of 27% from the average session volume of 2,512,730 shares. The stock had previously closed at $5.95.

A number of research firms recently issued reports on TXMD. Cantor Fitzgerald reissued a “buy” rating and set a $33.00 target price on shares of TherapeuticsMD in a research note on Monday. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $10.00 target price on shares of TherapeuticsMD in a research note on Thursday, August 31st. Deutsche Bank AG set a $10.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research note on Tuesday, August 22nd. Stifel Nicolaus reissued a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a research note on Monday, August 21st. Finally, Jefferies Group LLC reissued a “buy” rating and set a $15.00 target price on shares of TherapeuticsMD in a research note on Friday, August 11th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $16.14.

The stock’s market capitalization is $1.32 billion. The firm has a 50-day moving average price of $5.78 and a 200-day moving average price of $5.55.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. The company had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The firm’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.11) EPS. On average, analysts expect that TherapeuticsMD Inc will post ($0.44) earnings per share for the current year.

In other news, Director Tommy G. Thompson bought 5,000 shares of the stock in a transaction dated Wednesday, August 30th. The stock was bought at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the purchase, the director now directly owns 3,555 shares in the company, valued at approximately $21,294.45. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TXMD. Raymond James Financial Services Advisors Inc. lifted its stake in shares of TherapeuticsMD by 56.1% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after purchasing an additional 10,330 shares during the period. Greenwood Capital Associates LLC lifted its stake in shares of TherapeuticsMD by 17.5% in the 1st quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after purchasing an additional 3,022 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of TherapeuticsMD by 2.5% in the 1st quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock valued at $98,827,000 after purchasing an additional 329,245 shares during the period. Stifel Financial Corp lifted its stake in shares of TherapeuticsMD by 125.4% in the 1st quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after purchasing an additional 238,885 shares during the period. Finally, American International Group Inc. lifted its stake in shares of TherapeuticsMD by 7.1% in the 1st quarter. American International Group Inc. now owns 92,415 shares of the company’s stock valued at $665,000 after purchasing an additional 6,103 shares during the period.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/07/therapeuticsmd-inc-txmd-shares-up-6-9-2.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.